AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 131 min read$TAK

Furney Natalie Anne Marie sold $528K of TAK

Furney Natalie Anne Marie (Global General Counsel) sold 30,868 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $17.10 ($0.53M total) on 2026-08-10.

Original reporting
SEC EDGAR · Furney Natalie Anne Marie
Published Aug 13, 2026, 1:23 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TAK
Neutral
low confidence
Mentioned
$TAK
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TAKNeutralLow
01

Why it matters

The newest fact is the reported open-market sale by the Global General Counsel: 30,868 shares at $17.10 for about $527,842.80, with holdings after the sale of 204,298 shares and no pre-arranged 10b5-1 plan.

02

Market read

Traders may briefly reassess sentiment around insider behavior, but there is no fundamental catalyst in the text.

03

What to watch

The article does not state insider compensation needs, tax planning, or whether sales were part of broader personal liquidity actions; without that context, signal quality is low.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-12 after trade on 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for Takeda Pharmaceutical Co Ltd (TAK).

Company-level read

Ticker impact

$TAKNeutralLow confidence
Context

Takeda disclosed an officer open-market sale of 30,868 shares at $17.10 on 2026-08-10 via an SEC Form 4 filing.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven and typically fades.

Evidence & confidence

The filing provides transaction details only. Insider sales are common and the article includes no accompanying guidance, operational update, or regulatory/legal catalyst.

Market effects

Sector

No clear sector read-through; this is company-specific insider transaction data.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Absence of a 10b5-1 plan could be interpreted by some traders as less “mechanical,” potentially increasing short-term scrutiny.

Key entities

  • issuer
    TAK

    Takeda Pharmaceutical Co Ltd, the subject of the Form 4 insider sale disclosure.

  • insider
    Furney Natalie Anne Marie

    Global General Counsel who sold 30,868 shares in an open-market transaction.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TAK insider trading history →

Related articles

AUG 24
$TAKMedAI 8/10

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Takeda (TYO:4502/NYSE:TAK) announced Japan's approval of ORZEYFUL (oveporexton) for treating narcolepsy type 1 (NT1) in adults. The drug, discovered by Takeda, is the first to target the underlying cause of NT1. Approval follows successful Phase 3 trials showing significant symptom improvements. ORZEYFUL is also approved in China and the U.S.

thestarphoenix.com2 min
AUG 21
$TAKMedAI 8/10

Takeda Q1 adjusted EPS beats estimates despite slight sales dip

Takeda Pharmaceutical reported Q1 adjusted EPS of $0.48, beating estimates by 23.08%, with sales of $7.655 billion, up 8.42% from expectations but down slightly year-over-year. The company maintained its FY2026 guidance, noting currency headwinds and pipeline advancements, including regulatory approvals for ORZEYFUL and rusfertide. Positive Phase 3 results for zasocitinib in psoriasis were also announced, with submissions planned for regulatory approval.

scanx.trade3 min
AUG 18
$TAKMedAI 8/10

This Newly Approved Narcolepsy Drug Is the First to Target the Sleep Disorder’s Root Cause Rather Than Its Symptoms

The FDA approved Orzeyful, a narcolepsy type 1 drug by Takeda, targeting the root cause by mimicking orexin. Clinical trials showed improved wakefulness, sleep, and fewer cataplexy episodes. Takeda's CEO called it a new chapter for treatment. The drug may also have applications for ADHD and Parkinson's. According to experts, more research is needed, as not all patients lack orexin.

smithsonianmag.com4 min
AUG 8
$TAKMedAI 8/10

Takeda (TAK) Q1 2026 Earnings Call Transcript

Takeda (TAK) reported Q1 2026 revenue of JPY 1.22 trillion, up 10.2% on an actual FX basis but down 0.5% at constant rates, citing Vyvanse generic erosion offset by core brands. Core operating profit was JPY 358.9 billion and core EPS JPY 154. FY2026 guidance: revenue JPY 4.64 trillion, core op profit JPY 1.16 trillion, adjusted FCF JPY 650-750B. Orzeyful China approved; U.S./Japan expected in Q2 2026.

fool.com7 min